Answers are grounded in this paper and cite their sources.
During the past few years, the proprotein convertase subtilisin kexin 9 (PCSK9) field has been red hot, fueled by the realization that PCSK9 is a key player in plasma cholesterol metabolism and by a hope, shared by scientists in academia and industry alike, that PCSK9 is a target for treating hypercholesterolemia. PCSK9 regulates the levels of the LDL receptor (1–3), which is a plasma membrane glycoprotein that removes cholesterol-rich LDL particles from the plasma (4, 5). Gain-of-function mutations in PCSK9 reduce LDL receptor levels in the liver, resulting in high levels of LDL cholesterol in the plasma and increased susceptibility to coronary heart disease (6).
No takes yet. Share an insight, caveat, or question.
Peterson et al. (2008) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: